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Background: The Nurse Family Partnership programme was developed in the USA where it is made available to
pregnant young mothers in some socially deprived geographic areas. The related Family Nurse Partnership
programme was introduced in England by the Department of Health in 2006 with the aim of improving outcomes
for the health, wellbeing and social circumstances of young first-time mothers and their children.
Methods / design: This multi-centre individually randomised controlled trial will recruit 1600 participants from 18
Primary Care Trusts in England, United Kingdom. The trial will evaluate the effectiveness of Family Nurse Partnership
programme and usual care versus usual care for nulliparous pregnant women aged 19 or under, recruited by
24 weeks gestation and followed until the child’s second birthday. Data will be collected from participants at
baseline, 34-36 weeks gestation, 6, 12, 18 and 24 months following birth. Routine clinical data will be collected from
maternity, primary care and hospital episodes statistics. Four primary outcomes are to be reported from the trial:
birth weight; prenatal tobacco use; child emergency attendances and/or admissions within two years of birth;
second pregnancy within two years of first birth.
Discussion: This trial will evaluate the effectiveness and cost effectiveness of the Family Nurse Partnership in
England. The findings will provide evidence on pregnancy and early childhood programme outcomes for policy
makers, health professionals and potential recipients in three domains (pregnancy and birth, child health and
development, and parental life course and self-sufficiency) up to the child’s second birthday.
Trial registration: Trial registration number: ISRCTN23019866
Keywords: Pregnancy in adolescence, Prenatal care, Maternal health, Home visiting, Birth weight, Smoking cessation,
Child maltreatment, Family nurse partnership, Early years prevention, Randomised controlled trial* Correspondence: Owen-JonesCE@cardiff.ac.uk
1South East Wales Trials Unit (SEWTU), School of Medicine, Cardiff University,
Neuadd Meirionnydd 7th Floor, Heath Park, Cardiff, Wales CF14 4YS, UK
Full list of author information is available at the end of the article
© 2013 Owen-Jones et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Owen-Jones et al. BMC Pediatrics 2013, 13:114 Page 2 of 13
http://www.biomedcentral.com/1471-2431/13/114Background
Infants born into socioeconomic deprivation are more
likely to have teenage mothers, to have been exposed to
cigarette smoke during pregnancy, to have poor prenatal
health profiles, and are at greater risk of adverse short-term
and long-term outcomes [1-5]. In 2008 there were 44,691
live births to women under the age of 20 in England and
Wales [6]. Children born to teenage mothers have lower
birth weights, are less likely to be breast fed, exhibit higher
mortality rates, and are more likely to suffer accidents [7].
They do worse educationally, experience more emotional
and behavioural problems, and are more likely to become
teenage parents themselves [8].
Over one third of infants in the UK are exposed to
maternal smoking and 17% of mothers in England continue
to smoke throughout pregnancy [9-11]. Maternal smoking
in pregnancy impairs fetal growth - the average difference
in birth weight between infants born to smokers and to
non-smokers is about 250g [12]. This difference increases
with the amount smoked [13]. Smoking in pregnancy
increases the risk of miscarriage, premature birth, Sudden
Infant Death Syndrome (SIDS), emotional and behavioural
problems, cognitive problems in childhood, adolescent
criminal behaviour and adult violent and non-violent crime
[14-17]. Maternal smoking is also negatively associated
with breastfeeding initiation and duration [18].
Eight percent of babies born in the UK are of low birth
weight compared to seven percent in France and Germany
[19,20]. In addition to maternal smoking, risk factors for
low birth weight include being a teenage mother, infection
during pregnancy (causing preterm labour), family poverty
and social disadvantage [21]. Consequences of having a
low birth weight for gestational age or premature delivery
include neurological impairment and cognitive difficulties.
Adverse consequences of low birth weight on physical
health and psychological distress can be found much later
on in adult life [22,23].
In England, hospital and community based maternity
care is provided by the National Health Service, it is
universally available and free at the point of delivery.
Minimum standards for maternity care are recommended
by the National Institute for Clinical Excellence and in-
clude a minimum of 10 antenatal check-ups for women
expecting their first baby [24,25]. Specific additional care is
recommended for pregnant women under 20 and includes
allocating a named midwife to provide the majority of the
woman’s care, supported by direct telephone access [26].
Health Visitors (specialist community public health nurses)
provide support to new mothers and their children up
to the child’s fifth birthday with the level and nature of
engagement depending on local resources and individual
need.
Specific programmes to support the life chances of
children growing up in disadvantaged circumstances havealso been introduced in the United Kingdom. Sure Start
Local Programmes (SSLPs) were area-based interventions
for all children aged under 5, and involved local areas
improving and creating services to support young families.
Whilst SSLPs changed to come under the control of local
authorities and run from Children’s Centres, considerable
variation in delivery remained [27]. Furthermore, a more
targeted programme, Sure Start Plus was piloted with the
aim of reducing social exclusion associated with teenage
pregnancy by providing additional community based
support programmes and facilities. The pilot study of
Sure Start Plus showed enhanced parenting skills, but
less success in changing health damaging behaviours such
as smoking [28].
The Nurse Family Partnership (NFP) programme was
developed in the US to address the problems of poor
birth outcomes, social exclusion, child abuse and neglect,
and diminished economic self-sufficiency of socially disad-
vantaged younger first time mothers [29]. NFP is currently
offered in 42 US states [30]. The NFP is a structured,
intensive programme of home visits delivered by specially
trained nurses, provided from early pregnancy until the
child is two years old.
The NFP draws upon theories of human ecology, self-
efficacy and human attachment [31-33]. Visits cover core
content areas of personal and environmental health, life
course development, maternal role, family and friends and
access to health and social services. Time allocated to each
content domain is prescribed by the programme but
also varies over the duration of the programme. Maternal
behaviour change is supported through the promotion of
self-efficacy [34,35]. Education and modelling activities
are included in the programme to promote sensitive and
competent care giving via a strengths-based approach with
the aim of reducing maltreatment. A scheduled maximum
of 64 visits commence, ideally, early in the second trimes-
ter, and decrease in frequency over the first two years of
the child’s life. Whilst actual number of visits received
may vary by individual need, engagement, and gestational
age at enrolment, minimum targets are specified to support
desired programme outcomes. Programme goals are to
improve pregnancy outcomes, child health and develop-
ment, including a reduction in child maltreatment, and an
increase in maternal self-sufficiency.
In three randomised trials in the US, the NFP programme
improved prenatal health behaviours, birth outcomes,
sensitive child care, reductions in child injuries, abuse and
neglect, maternal life course (e.g. greater workforce par-
ticipation, fewer subsequent pregnancies, reduction in wel-
fare requirements), and child and adolescent functioning
[29,36-45]. The NFP had greatest impact amongst those with
low psychological resources. The cost of the programme
for low-income and unmarried mothers was recovered by
the child’s fourth birthday, whilst amongst married
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financial saving has been demonstrated over a longer
period [46].
NFP has been adapted for the UK where it is known
as the Family Nurse Partnership (FNP) programme and
is part of the Healthy Child Programme in England. Formal
evaluation has demonstrated that FNP is deliverable and
acceptable within the UK with some encouraging findings
in terms of outcomes [47-49]. Although there is evidence
of programme effectiveness in the US, there is no rigorous
trial evidence for FNP in the UK, which has universal
access to more comprehensive supportive care for young
first-time mothers [24,25]. It is this evidence of short-term
outcome effectiveness (up to the child’s second birthday)
that will be generated by the Building Blocks trial.
The trial is supported by a partnership between govern-
ment, research and primary and secondary care teams. In
2008, Primary Care Trusts (PCTs) in England tendered to
the Department of Health to provide the FNP programme
within the study context. The successful 18 PCTs subse-
quently employed the FNP teams to deliver the programme.
The Department of Health based FNP central team will
provide FNP materials, training and ongoing support to
the PCT local teams and maintain a central database of
FNP activity.
FNP teams are comprised of up to eight nurses, each of
whom carries a maximum caseload of 25 clients, a super-
visor who carries a reduced caseload, and an administrator.
This is similar to the NFP programme.
Research aim
The aims of our trial are to:
Aim 1: Evaluate the effectiveness of the FNP within
three outcome domains: pregnancy and birth, child
health and development, and parental life course and
self-sufficiency. Four primary outcomes have been
identified: birth weight, changes in prenatal tobacco
use, emergency attendances and hospital admissions for
the child within two years, and proportion of women
with a second pregnancy within two years. Primary and
secondary outcomes are listed in Tables 1 and 2.
Aim 2: Assess the incremental costs and consequences
of the FNP programme compared to existing services.
Aim 3: Model possible longer term costs and effects of
the FNP programme.
Aim 4: Evaluate what processes influence FNP outcomes
in order to explore applicability to other settings and to
optimise its future implementation.
Methods
Trial design
This trial is an individually randomised controlled trial with
a parallel economic modelling study. Trial participantseither receive usual universal services or usual universal
services along with regular visits from trained Family
Nurses (FN) from early pregnancy (of their first child)
until the child is two years old, following a prescribed
programme.Intervention
FNP
Participants in the intervention arm will receive up to
64 home based visits from the FNP nurse during their
pregnancy and in the two years following childbirth. Fidelity
requirements on programme recruitment and delivery are
specified by the developers of the US programme (Table 3).
In the UK, the Family Nurse provides the FNP pro-
gramme, alongside the usual maternity services during
pregnancy and the neonatal period. From one month to
two years after birth, the Family Nurse continues to provide
the programme undertaking the role of the Health Visitor.
Around the time of the child’s second birthday care is
handed over to a Health Visitor, whose input will vary
depending upon recognised need and local resources.
Family Nurses are recruited from existing registrants
on the Nursing Midwifery Council of the UK, mainly from
Health Visiting but also from Nursing and Midwifery.
Training in delivery of the programme will be provided to
the Family Nurses by the FNP central team.Usual care
Participants allocated to the usual care will receive care
from the local maternity services in line with usual prac-
tice. Following birth, the participants will continue to re-
ceive postnatal midwifery care and care from existing
child health services available locally, including an allo-
cated Health Visitor.Site and participant selection
Local consortia, comprising chiefly of individual Primary
Care Trusts (PCTs), and local authorities formally applied
to the Department of Health to be provider sites for FNP
and expressed willingness to participate in the randomised
trial. Each site was required to demonstrate sufficient
local clinical need and collectively to yield sufficient trial
recruits during the planned recruitment period.
The 18 selected trial sites are located in Barnsley,
Berkshire East, Cornwall, Coventry, Cumbria, Derby, Hull,
Lambeth, Leeds, Liverpool, Manchester, Northamptonshire,
South Birmingham, South East Essex, Southwark, Sunderland,
Tower Hamlets and Walsall. In most cases FNP will
be delivered across the whole area covered by each
PCT, but for some sites (e.g. Cornwall) availability of
the programme will be partially restricted to certain parts
of the PCT area.
Table 1 Maternal outcomes and assessment points




6 months 12 months 18 months 24 months HES / GP2
Socioeconomic
Not in education, employment or training
(NEET status) [50,51]
x x x x x
Hours in formal education [50,51] x x x x
In paid employment [50,51] x x x x x
Type of employment [50,51] x x x x x
In receipt of benefits [50,51] x x
Other financial support [50,51] x x
Ever been homeless (Millennium Cohort Study) [50,51] x x x x x
Maternal health & well-being
General health status (EQ-5D) [52] x x x x x x
Weight / BMI (Millennium Cohort Study) [50,51] x x
Psychological distress (Kessler scale) [53] x x
Depression (Whooley scale) [54] x x x x
Postnatal depression (Edinburgh PDS) [55] x
Self-efficacy (Generalised Self-efficacy Scale) [56] x x x x x
Adaptive functioning [57,58] x x
Intimate partner violence (Composite Abuse Scale) [59] x
Health behaviour
Tobacco use3 x x x
Smoking cessation method (if applicable) [60,61] x x
Smoke in home x x x
Problem alcohol and drug use (CRAFFT) [62] x x
Contraceptive use and method
(Millennium Cohort Study) [50,51]
x x x x x
Pregnancy and birth
Gestation at delivery x
Place of birth (planned, actual) x
Subsequent pregnancies3 x x x x x
Social support
Social support and networks (MOS Survey) [63,64] x x x x x
Family resources [65] x x x x x
Relationship quality (Golombok Rust Inventory of
Marital State) [66]
x x x x x x
Use of services
Dental care x
Antenatal care (check-ups, planned / unplanned
attendances)
x x
Primary care or secondary care attendance / admission x x x x x
Additional non-health (education, social, childrens,
Connexions) services
x x x x
Foster care (mother, baby, both) x x x x
1 Name of validated measure (items amended or partially sourced from existing measures indicated by citation only) 2 For period from recruitment or birth until
24 months (mother and child); 3 Primary outcome domain.
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Table 2 Parenting and child outcomes and assessment points




6 months 12 months 18 months 24 months HES / GP2
Parenting beliefs, behaviour and experience
Anticipatory parenting (Millennium Cohort Study) [50,51] x
Infant feeding intentions x
Prenatal attachment [67] x
Parental role strain (Millennium Cohort Study) [50,51] x x x x
Maternal-child interaction [68] x




Apgar score (1, 5 mins) x
Head circumference x
Neonatal unit admission x
Feeding & development
Breastfeeding initiation, duration x x x x
Baby diet x x
Cognitive development [69] x x x
Language development (Early Language
Milestone Scale) [69,70]
x x x
Child safety [71] x x x
Health and use of services
Childcare x x x x
Immunisations x x x x
Emergency attendances & admissions (all cause)3 x x x x x x
Primary care consultation (injuries & ingestions) x x x x x
Medically attended injuries & ingestions x x x x x x
Referral from primary care (social care, other,
safeguarding)
x x
1 Name of validated measure (items amended or partially sourced from existing measures indicated by citation only) 2 For period from recruitment or birth until
24 months (mother and child); 3 Primary outcome domain.
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Local researchers (usually a midwife or nurse), will be
employed at each trial site, and trained by the trial team
prior to their site opening to recruitment and annually
thereafter. Topics to be covered during the training sessions
will include an overview of the trial, the FNP programme,
obtaining consent and recruitment procedures. Emphasis
will be placed on the assessment of the competence of
potential trial participants to provide consent, explaining
both arms of the trial without bias, trial outcomes, serious
adverse event monitoring and reporting, and withdrawals.
Later training will cover follow-up rates, retention
strategies, birth related data collection, organising and
conducting the 2 year home based interview, data collec-
tion from primary care records and conducting research
interviews.The role of a local researcher will be to recruit partici-
pants, maintain current contact details for participants and
conduct home based interviews and assessments in their
trial site. South East Wales Trials Unit, Cardiff University,
in collaboration with Bristol University, University of York
and University of South Wales (formerly University of
Glamorgan) will implement the trial.
Eligibility criteria
Eligibility criteria will match FNP programme enrolment
criteria as closely as possible and are listed in full in
Table 4. Recruits will be nulliparous, aged 19 or under,
and will be recruited to the trial no later than 24 weeks
gestation (and ideally within the first 15 weeks). This was
to enable enrolment to the FNP (for those randomised to
the intervention arm) in line with the programme fidelity
Table 3 FNP fidelity goals [47,48,72]
FNP fidelity goals Criteria
Recruitment and
enrolment
• at least 60% enrolled before 16 weeks of
pregnancy and 100% no later than 28 weeks
• 100% of clients enrolled are first-time mothers
• 100% of clients enrolled are 19 years or younger
at LMP
• 75% of eligible clients who are offered the
programme are enrolled
• each family nurse enrols 25 families (or pro rata)
within 9 months of recruitment
Attrition Clients leave the programme at no more than
these rates:
• cumulative programme attrition is 40% or less
through to the child’s second birthday
In detail:
• 10% or less during the pregnancy phase
• 20% or less during the infancy phase
• 10% or less during toddlerhood
Dosage Clients receive:
• 80% or more of expected visits during
pregnancy
• 65% or more of expected visits during infancy
• 60% or more of expected visits during
toddlerhood
On average, length of home visits is around
60 minutes
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gestation, and all by 28 weeks [47,48,72]).
Recruitment
Potential participants will be identified in conjunction
with staff from antenatal clinics. Women may also either
self-identify or be referred via other services including
GP surgeries into the study. Referral pathways will be
tailored to accommodate local variations in clinical practice
pathways and services at each site. Trial information will
be made available at local clinics (midwifery clinics, GPTable 4 Participant inclusion/exclusion criteria
Inclusion criteria Exclusio
1. Women aged 19 or under (at recruitment / consent). 1. Wome




3. First pregnancy confirmed by health services (including those
expecting multiple births) unless previous pregnancy ended in
miscarriage, stillbirth or termination.
3. Wome
to rece
4. Recruited no later than 24 weeks gestation.
5. Gillick competent to provide informed consent to research
participation including competence in English at conversational
level or higher.surgeries, Children’s Centres, Local Connexions Offices).
During the study recruitment period women in study sites
will only be able to enrol in the FNP programme via
participation in the trial. Direct referrals to the FNP
team will be passed back to the Local Researcher to discuss
trial participation.
Local Researchers will contact identified potential
participants to arrange a recruitment visit where they will
be provided with an information pack explaining the trial.
Adequate time will be given for reading the material and
asking any questions. Women will be encouraged to
discuss the trial with friends and family, if needed, before
deciding about participation. Informed, written consent
will be obtained by the local researcher.Randomisation
Prior to recruitment of a trial participant, the Local
Researcher will confirm that the local FNP team has
spare capacity, consent will be obtained and the baseline
assessments completed. The Local Researchers will use a
remote randomisation service (automated telephone or
web) provided by Bristol Randomised Trials Collaboration
(BRTC) to allocate the woman to FNP or usual care. The
Local Researcher will inform the FNP team of participants
allocated to receive the programme. The FNP team will
then take responsibility to enrol the woman into the
programme and provide the intervention. For women
allocated to usual care, the woman’s community midwife
will be informed. All participants’ General Practitioners
will be notified of their recruitment to the trial.
A randomisation algorithm will minimise by gesta-
tion at recruitment (<16 weeks/16 weeks+), smoking
status at recruitment (smoker/non-smoker) and first
language/preferred language (English/non-English) for
each site with a probability of 0.8. Therefore a random
element is retained, further reducing predictability of
allocation. The trial statisticians and economists will
be blinded to treatment allocation until analyses are
complete.n criteria
n who at study entry, plan to have their child adopted.
n who at study entry, plan to leave the FNP area during the time of the
r for an extended period of time (3 months or longer) or permanently.
n who would require a third person (translator, sign interpreter)
ive the FNP programme.
Owen-Jones et al. BMC Pediatrics 2013, 13:114 Page 7 of 13
http://www.biomedcentral.com/1471-2431/13/114Frequency and duration of follow-up to assess study
outcomes
Follow-up will continue until the child’s second birthday.
Following the baseline home assessment, women will be
followed up by qualified and specially trained telephone
interviewers at 34-36 weeks gestation, then at six months,
twelve months, and eighteen months postnatally. A final
home-based face-to-face interview will be conducted two
years after birth. The interviewers will follow procedure-
specific Standard Operating Procedures with regards to
serious adverse event reporting and child safeguarding
issues.
A urine sample for cotinine assessment will be collected
at the baseline visit and also at 34-36 weeks gestation.
Following birth, medical and obstetric history items,
antenatal attendances, and maternal and neonatal birth
outcomes will be extracted from medical records onto a
Case Report Form. Data relating to the number, duration
and content of Family Nurse visits to participants will be
captured on a Department of Health database which the
trial team will access. The timing and methods of data
collection are summarised in Figure 1.
Retention strategy
Local researchers will be the main point of contact between
the trial team and trial participants and will have a key role
in maintaining participant engagement with the trial. They
will update participant contact details, monitor for adverse
events and promote progress of the trial. The trial team will
visit sites prior to initiation, and run central training days
where all the local researchers get to know one another,
share best-practice procedures and be trained in how to
carry out subsequent trial phases.
To maintain engagement with trial participants, based
on suggestions from local stakeholders including young
mothers, we will use vouchers for telephone airtime, birth-
day cards and presents for the baby, contacts from the local
researcher, and use of SMS texting. High Street vouchers
to the value of £25, £25 and £40 will be given after comple-
tion of the 12, 18 and 24-month interviews respectively to
acknowledge their time commitment to data collection. A
first year birthday gift will be sent and a second year
birthday gift will be given on completion of the two year
interview. Prior notification of telephone interviews will
be via SMS messages to participants. A participant website
will be used to encourage engagement of participants.
Primary outcomes
Four primary outcomes are to be reported from the trial
(Tables 1 and 2):
 Birth weight (grams).
 Prenatal tobacco use: calibrated number of cigarettes
per day at 34-36 weeks gestation [73]; Emergency attendances and/or admissions within two
years of birth: proportion of participants’ children
attending Accident and Emergency (A&E) or having
an emergency admission to hospital within two
years of birth.
 Second pregnancy within two years of first birth:
proportion of women with a subsequent pregnancy
within two years of first birth.
Secondary outcomes
Secondary outcomes are shown in Tables 1 and 2. Where
validated scales will be used these are named and
referenced; where validated scales will be modified or
items selected, these are shown with a citation only; other
outcome variables will be newly derived.
Sample size estimation
A total sample of 1418 for analysis will provide at least
90% power at the two-sided 2.5% alpha level to detect
differences between the two arms of 10% (40% to 30%)
in the proportion having any emergency attendance or
emergency admission to hospital within two years, and
of 7.5% (20% to 12.5%) in the proportion with a second
pregnancy within two years. For each outcome measure,
the expected improvement for the FNP arm relates to a
small standardised difference (approx. 0.2 or odds ratio
0.6). This small standardised difference will enable us to
detect effect towards the lower end of what we expect.
We will allow for a pregnancy loss of 1.5%.
We expect to obtain follow-up data for three of the
four primary outcomes on at least 90% of participants by
accessing the medical records in hospital and primary
care for both the mother and child. Follow-up smoking
rates will be collected through the late pregnancy telephone
interviews. We will therefore aim to recruit a total of 1600
pregnant women to achieve our target number for analysis,
as this takes into account anticipated pregnancy loss and
loss to follow up.
We have chosen to use a 2.5% alpha level to allow for
multiple primary outcomes within each individual popu-
lation in the trial – i.e. there are two primary outcomes
for the mother (smoking and second pregnancy) and two
for the baby (birth weight and emergency attendances/
admissions). This gives a 5% type 1 error rate for each
population.
Stakeholder involvement and ethics
A Stakeholder Involvement and Ethics Group will be
responsible for working across the trial, economic and
process evaluations. We recognise that pregnant teenagers
are a vulnerable group, at greater risk of social exclusion
(e.g. from lower socioeconomic groups, care leavers). Con-
sequently, various sensitive and practical issues need con-
sideration prior to study commencement, for example,
Figure 1 Participant flow diagram and data collection.
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followed in the event of child safeguarding concerns. The
Stakeholder Group will work to identify potential issues
that may arise during the course of the trial and advise
on their appropriate management. This will entail the
development of a range of Stakeholder Groups to support
the conduct of the trial through the various stages of
development to completion.
The collaborative involvement of lay and professional
people in the Stakeholder Groups will provide added value
to the trial teams. Public contributors will be part of core
trial management groups: Trial Steering Committee, the
Stakeholder Management Group and the Independent Data
Monitoring Committee. Reference groups, including young
mothers, will be set up to advise on trial information mate-
rials, provide advice at the different stages of the trial, and
contribute towards the design of the trial participant website.Process evaluation
The process evaluation will aim to understand variations in
the impact of the intervention and to contextualise findings
[74]. Routine FNP monitoring data will be integrated
with planned process evaluations using quantitative and
qualitative methods [75].
The process evaluation will examine
 fidelity to programme content and style of programme
delivery, and to pre-set frequency and duration
targets
 participants’ engagement and satisfaction with FNP
 impact of FNP roll-out as perceived by local stakeholders
(FNP teams, HealthVisitors, Midwives)
 wider contextual influences on programme implement-
ation and outcomes
Owen-Jones et al. BMC Pediatrics 2013, 13:114 Page 9 of 13
http://www.biomedcentral.com/1471-2431/13/114Fidelity targets for FNP visits prescribe time allocation
for different content domains. In the UK, delivery of the
programme is integrated with Motivational Interviewing
(MI) [76] which forms part of the foundation of the
FNP. Fidelity assessment will include audio-recording a
sample of home visits for women at each site (n=216).
Recordings will be assessed for consultation content and
MI competencies using thematic content coding and a
validated scale measuring adherence to Motivational
Interviewing techniques [77]. Dose will be assessed by
comparing FNP monitoring data against set performance
metrics. Interviews with a sample of FNP clients (n=72)
will assess intervention exposure; participants in the
non-intervention arm of the trial will not be interviewed.
Trial recruitment and retention will be assessed by
examining sample characteristics and attrition rates and
predictors.
Evaluation of context will focus on mapping existing
universal services using questionnaires with key informants
at each site and accessing national and local policy guide-
lines and commissioning briefs. Planned analysis of trial
outcome data will explore differential programme impact
across practitioners, sites and sample sub-groups.
Further contextual factors affecting implementation and
potential wider roll-out will be explored in telephone
interviews with FNP supervisors and focus groups with
FNP teams and other local Stakeholders (Midwives, Health
Visitors). Assessing contamination will form part of the
structured telephone interviews with local stakeholders
and the focus group discussions.
Health economics and modelling
Intervention effects will extend beyond the health sector,
both within the timeframe of the trial and in the future.
Therefore two components of work are required: one to
explore the relative value of effects within the different
sectors (health, social care, education, criminal justice)
and another to consider the longer term extrapolation of
trial results (i.e. over the lifetime of the child). To inform
both of these, a literature review of economic outcomes
within criminal justice and education literature will be
conducted.
Valuation of effects: preference elicitation work will be
undertaken in order to measure the relative values that
members of the general public place on the different
outcomes of the trial. Specifically, a discrete choice experi-
ment and a best-worst scaling exercise will be conducted.
This work will consider the trade-offs that people are
prepared to make between benefits in the different sectors,
which will inform the relative magnitude of benefits
accruing to different sectors.
Economic extrapolation: the extrapolation exercise
will seek to link the primary outcomes of the trial with
longer term outcomes in health, education, employmentand criminality extending to the childhood and adulthood
of the index baby, and the mother. A literature review
will be conducted to capture studies that examine the
association between the short term primary outcomes,
as measured in the trial, and the longer term outcomes.
The inclusion of the studies will be done in stages, where
cohort studies of longitudinal nature that enrolled partici-
pants at birth stage or prenatally and were conducted in
the UK will be prioritised. The results of the literature
review will be summarized in a narrative way and all the
links will be presented in a tabulated format. The results
of the review will be interpreted in light of the FNP trial
results.
Statistical analysis
Main analysis – primary outcomes
The primary comparative analyses will be conducted on
an intention-to-treat basis, with an emphasis placed on
confidence intervals for differences between the randomised
arms.
Descriptive statistics of demographic and outcome mea-
sures will be used to ascertain any marked imbalance
between the arms at baseline. For birth weight and
prenatal tobacco use at 34-36 weeks the primary compara-
tive analyses will employ multivariable linear regression
to investigate differences between the arms, adjusting for
stratification/ minimisation variables. In the case of prenatal
tobacco use the calibrated number of cigarettes per day
reported at baseline will also be adjusted for. The result will
be presented as the (adjusted) difference in mean number
of cigarettes per day between the intervention and control
arms. Parameter estimates will be shown alongside 95%
confidence intervals (CIs) and p-values.
For the proportion of children with at least one emer-
gency attendance and/or admission and proportion of
women with known subsequent pregnancies, logistic re-
gression will be used adjusting for stratification/minimisa-
tion variables. Comparisons will be presented as odds
ratios, 95% CIs and p-values.
Multilevel modelling will be used to allow for clustering
of effect within a site and Family Nurse. Where this
analysis indicates little impact of clustering on effect then
the results from the single level model will be presented.
Sensitivity analyses will be conducted to investigate the
potential impact of missing data, making different as-
sumptions such as ‘best’ and ‘worst’ case scenarios as
well as imputation models. Where variables exhibit
marked imbalance at baseline, primary analyses will be
repeated and adjustments will be made to check that
this does not influence findings. The same analyses will be
carried out for the secondary outcomes depending on the
type of data.
Appropriate interaction terms will be entered into the
primary regression analyses for each of the outcomes in
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subgroups will be defined by the Trial Management
Group in advance of any analysis being started with input
from the trial team and summaries of current evidence
from the literature. Since the trial is powered to detect
overall differences between the arms rather than interac-
tions of this kind, the results of these exploratory analyses
will be presented using confidence intervals as well as
p-values.
Routine data on compliance with the FNP and usual
maternity and early childhood services will be collected
and utilised in understanding any outcome differences
between the two arms.
Process evaluation analysis
To establish internal validity, a sample of audio-recorded
pregnancy, infancy, and toddlerhood home visits will be
compared for self-reported and independently established
programme content, using descriptive statistics. Similarly,
a sample of FNP practitioners will be examined on the MI
specific competency of their programme delivery using
the Motivational Interviewing Treatment Integrity (MITI)
validated scale ratings [77]. Dose and structure of visits
will be monitored and compared to pre-set targets.
Recruitment and retention to the trial will be monitored
on an ongoing basis. Contamination between trial arms
will be established using descriptive statistics from the
service mapping survey and follow-up trial questionnaires.
The full trial data set will be subjected to subgroup
analyses to determine potential environment influences
on implementation and outcomes.
Cost effectiveness/health economics analysis
Costs
For the primary analysis, the resource use data related to
health care services utilised by the trial participants such as
GP visits, hospital overnight stays, accident and emergency
attendances will be considered. These data will be collected
for both intervention and control arm from self-reported
questionnaires, the NHS Hospital Episode Statistics and
patient records held at GP practices. For the secondary
analyses, in addition to the health care resource usage,
non-health care costs will be included. These relate to
services such as social assistance, housing, education
and criminal justice. The data for this type of resource usage
will be collected from the self-reported questionnaires.
The cost of the intervention will be assessed based on
the routine data collected by the FNP nurses and input
into the central Department of Health FNP database.
This includes information directly related to the FNP
utilisation such as the number and percentage of completed
visits by the FNP nurses as well as their duration, and
the number of telephone encounters with the client. In
addition, the database includes information on thequalifications of the FNP nurses which will be used to
assess the remuneration bracket of the nurses for the
overall costing of this service.
Outcomes
For the economic analysis, the same primary outcomes
that have been considered in the statistical analysis will be
used. These will be analysed and reported as outcomes in a
cost-consequences analysis or, wherever this is appropriate,
in a cost-effectiveness analysis. Where data allow, these
effectiveness estimates will be linked to utility scores and a
cost-utility analysis will be conducted. A cost-utility analysis
will be used for estimating the impact of the programme
on maternal health. The outcome for this analysis is mea-
sured by calculating quality-adjusted life years (QALYs).
Direct estimation of QALYs is not possible for children
as they will be too young during the trial, but we will
estimate the intervention impact upon the mothers using
the EQ-5D. The cost-utility analysis will be based on the
QALYs difference of the mothers between the two arms
from 34-36 weeks gestation of the index child and up
to the second birthday of that child, when the trial is
completed.
Unit costs
Unit cost estimates will be applied to resource use data
to generate individual level cost estimates. Sources of
unit costs will include routine or published literature
such as the latest Personal Social Services Research Unit
(PSSRU) Unit Costs of Health and Social Care [78] and the
latest NHS Reference Costs [79]. In addition, published
sources and information from local health care providers
will be sought. For the non-health related resources, unit
costs will be sought from the relevant sources such as
governmental websites.
Data analysis and presentation of the results
Two types of analyses will be conducted: a complete case
analysis (CCA) and an analysis by using multiple imput-
ation methods; both analyses will include allowance for
the clustered nature of the data. In the ‘complete case ana-
lysis’ only trial participants with available total costs and
primary outcomes will be included. In the multiple imput-
ation analysis all participants with partial information on
resource usage and outcomes will be included. Missing
values will be imputed by using multiple imputation (MI)
methods. A range of sensitivity analyses will be conducted
to test the robustness of the results under different scenar-
ios. These scenarios will capture variability in the estimates
of cost and outcomes, which result from either different
methods (e.g. imputation methods) or from different sources
of data (e.g. unit cost data).
Incremental cost-effectiveness ratios (ICERs) will be cal-
culated where appropriate. These demonstrate the mean
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egies, i.e. the incremental cost per QALY gained will be
presented. The mean differences in costs and effects be-
tween the two arms of the trial will be estimated by
using a regression based approach (allowing for covariate
adjustment and subgroup analyses) and the 95% confi-
dence intervals around those will be estimated by using
bias corrected and accelerated bootstrapped methods. Cost
effectiveness acceptability curves (CEACs) will be gener-
ated through the use of probabilistic sensitivity analysis.
The CEAC will plot the probability of the intervention
being cost-effective for a range of threshold values of an
additional QALY.
Ethical and governance approval
Multi-centre approval has been granted by the Research
Ethics Committee for Wales (ref. no. 09/MRE09/8).
Site-specific approval has been granted at all participating
Primary Care and Acute Trusts.
Adverse event monitoring
We will apply a procedure for the monitoring and reporting
of serious adverse events (SAEs). These will be reported
to the trial team by the local researchers, telephone inter-
viewers and any other member of the local clinical team.
Given the anticipated high number of pregnancy related
hospital attendances and admissions, SAEs will be further
assessed to identify those that are clinically complex or
serious.
Discussion
The aim of the trial is to determine whether there are
important, significant differences in maternal and child
outcomes during pregnancy, at birth and until the child’s
second birthday between pregnant teenagers who are
offered FNP and to those offered usual care in England.
Whilst there is evidence for the effectiveness of NFP
from the US before the child’s second birthday, the main
benefits of the NFP programme have been seen later in
childhood. Therefore lack of overall programme impact
cannot be concluded if this trial finds a lack of effect in
the pregnancy and birth domain.
Although increased birth weight is not a direct aim of
FNP, there may be an impact if rates of smoking and
other lifestyle factors are influenced by the programme.
Due to the clinical importance of birth weight and the
availability of reliable data this has been included as a
primary outcome for the child. A planned subgroup ana-
lysis of birth weight will be undertaken for mothers who
smoke at baseline.
The Building Blocks randomised controlled trial has
been designed to estimate impacts on outcomes occurring
amongst recipients of FNP compared to routine care. As
benefits of the FNP can accrue following completion ofthe programme, the trial includes measures which could
be predictive of longer-term outcomes. At the two-year
follow-up assessment (at the end of the trial), further
permission will be sought to contact the trial participants
to enable longer term follow-up beyond the end of the
current trial period.
This trial provides an example of an evaluation of
government policy. This inevitably requires management
of complex interactions between a government department
delivering the policy, local providers of services, locally
employed researchers and university based academics.
With 18 trial sites covering urban and rural settings and
each with unique service provision and populations, the
trial team will be required to adapt procedures and path-
ways to meet local need, and preserve intervention fidelity
whilst maintaining the integrity of the randomised trial.
The challenges in the delivery of this trial will be complex
and many. In addition to the coordination required to
maintain engagement in 18 PCT sites spread across major
cities and some rural areas in England, the trial will also
need to engage staff groups employed by 23 NHS Trusts
that provide hospital based maternity care. Specific chal-
lenges related to trial setup include the recruitment and
appointment of 18 locally NHS employed researchers and
the identification of suitable but flexible recruitment path-
ways. Participants will be active in the trial for over 2 years
during which time many are expected to several change
their address and other contact details. To overcome such
challenges, inevitable in this trial design, an age appropri-
ate, comprehensive retention strategy will be developed,
alongside usual intensive trial management procedures.
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